{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:07:45Z","timestamp":1790636865899,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2458-12-398","type":"journal-article","created":{"date-parts":[[2012,6,7]],"date-time":"2012-06-07T05:55:20Z","timestamp":1339048520000},"source":"Crossref","is-referenced-by-count":71,"title":["Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study"],"prefix":"10.1186","volume":"12","author":[{"given":"Linda J","family":"Cobiac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Magnus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J","family":"Barendregt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,1]]},"reference":[{"key":"4911_CR1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5694\/j.1326-5377.2008.tb01503.x","volume":"188","author":"S Begg","year":"2008","unstructured":"Begg S, Vos T, Barker B, Stanley L, Lopez A: Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust. 2008, 188: 36-40.","journal-title":"Med J Aust"},{"key":"4911_CR2","volume-title":"Health expenditure Australia 2007\u201308","author":"AIHW","year":"2009","unstructured":"AIHW: Health expenditure Australia 2007\u201308. 2009, Canberra: Australian Institute of Health and Welfare"},{"key":"4911_CR3","volume-title":"Taking Preventative Action \u2013 A response to Australia: The Healthiest Country by 2020 \u2013 the report of the National Preventative Health Taskforce","author":"Australian Government Australian Government","year":"2010","unstructured":"Australian Government Australian Government: Taking Preventative Action \u2013 A response to Australia: The Healthiest Country by 2020 \u2013 the report of the National Preventative Health Taskforce. 2010, Canberra: Commonwealth of Australia"},{"key":"4911_CR4","volume-title":"National Chronic Disease Strategy","author":"National Health Priority Action Council","year":"2006","unstructured":"National Health Priority Action Council: National Chronic Disease Strategy. 2006, Canberra: Australian Government Department of Health and Ageing"},{"key":"4911_CR5","doi-asserted-by":"publisher","first-page":"b2376","DOI":"10.1136\/bmj.b2376","volume":"338","author":"JJ Brugts","year":"2009","unstructured":"Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, de Craen AJM, Knopp RH, Nakamura H, Ridker P, et al: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009, 338: b2376-10.1136\/bmj.b2376.","journal-title":"BMJ"},{"key":"4911_CR6","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J. 2009, 338: b1665-10.1136\/bmj.b1665.","journal-title":"Br Med J"},{"key":"4911_CR7","volume-title":"Diabesity and associated disorders in Australia - 2000, The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)","author":"D Dunstan","year":"2001","unstructured":"Dunstan D, Zimmet P, Welborn T, Sicree R, Armstrong T, Atkins R, Cameron A, Shaw J, Chadban S: Diabesity and associated disorders in Australia - 2000, The Australian Diabetes, Obesity and Lifestyle Study (AusDiab). 2001, Melbourne: International Diabetes Institute"},{"key":"4911_CR8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5694\/j.1326-5377.2002.tb04430.x","volume":"176","author":"JW Sturm","year":"2002","unstructured":"Sturm JW, Davis SM, O'Sullivan JG, Vedadhaghi ME, Donnan GA: The Avoid Stroke as Soon as Possible (ASAP) general practice stroke audit. Med J Aust. 2002, 176: 312-316.","journal-title":"Med J Aust"},{"key":"4911_CR9","unstructured":"Department of Health and Ageing: PBS - Eligibility criteria for lipid lowering drugs. [ http:\/\/www.hirc.health.gov.au\/internet\/main\/publishing.nsf\/Content\/lipid_eligibilitycriteria.htm ],"},{"key":"4911_CR10","volume-title":"Diabetes managment in general practice","year":"2009","unstructured":"Diabetes managment in general practice. Edited by: Harris P, Mann L, London J, Phillips P, Webster C. 2009, Diabetes Australia, 15","edition":"15"},{"key":"4911_CR11","volume-title":"Hypertension management guide for doctors. 2004","author":"National Heart Foundation","year":"2004","unstructured":"National Heart Foundation: Hypertension management guide for doctors. 2004. 2004, National Heart Foundation of Australia"},{"key":"4911_CR12","volume-title":"Guide to management of hypertension","author":"National Heart Foundation","year":"2008","unstructured":"National Heart Foundation: Guide to management of hypertension. 2008, National Heart Foundation of Australia"},{"key":"4911_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1001\/archinternmed.2009.434","volume":"170","author":"BS Ferket","year":"2010","unstructured":"Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, Steyerberg EW, Hunink MGM: Systematic Review of Guidelines on Cardiovascular Risk Assessment: Which Recommendations Should Clinicians Follow for a Cardiovascular Health Check?. Arch Intern Med. 2010, 170: 27-40. 10.1001\/archinternmed.2009.434.","journal-title":"Arch Intern Med"},{"key":"4911_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(03)12655-4","volume":"361","author":"CJL Murray","year":"2003","unstructured":"Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, Lawes CMM, Evans DB: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003, 361: 717-725. 10.1016\/S0140-6736(03)12655-4.","journal-title":"Lancet"},{"key":"4911_CR15","volume-title":"Guidelines for the assessment of absolute cardiovascular disease risk","author":"National Vascular Disease Prevention Alliance","year":"2009","unstructured":"National Vascular Disease Prevention Alliance: Guidelines for the assessment of absolute cardiovascular disease risk. 2009, National Heart Foundation of Australia"},{"key":"4911_CR16","volume-title":"Population by Age and Sex, Australian States and Territories, Jun 2009","author":"ABS","year":"2009","unstructured":"ABS: Population by Age and Sex, Australian States and Territories, Jun 2009. 2009, Canberra: Australian Bureau of Statistics"},{"key":"4911_CR17","first-page":"128","volume-title":"General Practice in Australia","author":"J Beilby","year":"2005","unstructured":"Beilby J, Furler J: General practitioner services in Australia. General Practice in Australia. 2005, Commonwealth of Australia, 128-213."},{"key":"4911_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","volume":"121","author":"K Anderson","year":"1991","unstructured":"Anderson K, Odell P, Wilson P, Kannel W: Cardiovascular disease risk profiles. Am Heart J. 1991, 121: 293-298. 10.1016\/0002-8703(91)90861-B.","journal-title":"Am Heart J"},{"key":"4911_CR19","volume-title":"New Zealand Cardiovascular Guidelines Handbook: A summary resource for primary care practitioners","author":"New Zealand Guidelines Group","year":"2009","unstructured":"New Zealand Guidelines Group: New Zealand Cardiovascular Guidelines Handbook: A summary resource for primary care practitioners. 2009, Wellington: Ministry of Health"},{"key":"4911_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0140-6736(03)13968-2","volume":"362","author":"M Ezzati","year":"2003","unstructured":"Ezzati M, Vander Hoorn S, Rodgers A, Lopez AD, Mathers CD, Murray CJL: Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet. 2003, 362: 271-280. 10.1016\/S0140-6736(03)13968-2.","journal-title":"Lancet"},{"key":"4911_CR21","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/bmj.321.7268.1084","volume":"321","author":"L Simons","year":"2000","unstructured":"Simons L, Simons J, McManus P, Dudley J: Discontinuation rates for use of statins are high [Letter]. BMJ. 2000, 321: 1084-10.1136\/bmj.321.7268.1084.","journal-title":"BMJ"},{"key":"4911_CR22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5694\/j.1326-5377.2008.tb01589.x","volume":"188","author":"LA Simons","year":"2008","unstructured":"Simons LA, Ortiz M, Calcino G: Persistence with anti hypertensive medication: Australia-wide experience, 2004\u20132006. Med J Aust. 2008, 188: 224-227.","journal-title":"Med J Aust"},{"key":"4911_CR23","volume-title":"Pharmaceutical Benefits Schedule","author":"PBS","year":"2008","unstructured":"PBS: Pharmaceutical Benefits Schedule. 2008, Canberra: Department of Health and Ageing, Commonwealth of Australia"},{"key":"4911_CR24","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003, 326: 1427-","journal-title":"BMJ"},{"key":"4911_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","volume":"35","author":"TC Weng","year":"2010","unstructured":"Weng TC, Yang YHK, Lin SJ, Tai SH: A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010, 35: 139-151. 10.1111\/j.1365-2710.2009.01085.x.","journal-title":"J Clin Pharm Ther"},{"key":"4911_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","volume":"35","author":"TC Weng","year":"2010","unstructured":"Weng TC, Yang YHK, Lin SJ, Tai SH: A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010, 35: 139-151. 10.1111\/j.1365-2710.2009.01085.x.","journal-title":"J Clin Pharm Ther"},{"key":"4911_CR27","volume-title":"Pharmaceutical Schedule","author":"PHARMAC","year":"2010","unstructured":"PHARMAC: Pharmaceutical Schedule. 2010, New Zealand: Pharmaceutical Management Agency"},{"key":"4911_CR28","volume-title":"The WHO MONICA Study, Australia, 1984\u201393: A summary of the Newcastle and Perth MONICA projects","author":"P McElduff","year":"2000","unstructured":"McElduff P, Dobson A, Jamrozik K, Hobbs M: The WHO MONICA Study, Australia, 1984\u201393: A summary of the Newcastle and Perth MONICA projects. 2000, Canberra: Australian Institute of Health and Welfare"},{"key":"4911_CR29","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1161\/01.STR.31.9.2087","volume":"31","author":"A Thrift","year":"2000","unstructured":"Thrift A, Dewey H, Macdonell R, McNeil J, Donnan G: Stroke Incidence on the east coast of Australia: The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2000, 31: 2087-2092. 10.1161\/01.STR.31.9.2087.","journal-title":"Stroke"},{"key":"4911_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1071\/AH080148","volume":"32","author":"S Begg","year":"2008","unstructured":"Begg S, Vos T, Goss J, Mann N: An alternative approach to projecting health expenditure in Australia. Aust Health Rev. 2008, 32: 148-155. 10.1071\/AH080148.","journal-title":"Aust Health Rev"},{"key":"4911_CR31","volume-title":"General practice activity in Australia 1999\u201300 to 2008\u201309: 10\u2009year data tables","author":"H Britt","year":"2009","unstructured":"Britt H, Miller G, Charles J, Henderson J, Bayram C, Valenti L, Pan Y, Harrison C, Fahridin S, O\u2019Halloran J: General practice activity in Australia 1999\u201300 to 2008\u201309: 10\u2009year data tables. 2009, Canberra: Australian Institute of Health and Welfare"},{"key":"4911_CR32","volume-title":"Medicines for cardiovascular health: are they used appropriately?","author":"S Senes","year":"2007","unstructured":"Senes S, Penm E: Medicines for cardiovascular health: are they used appropriately?. 2007, Canberra: Australian Institute of Health and Welfare"},{"key":"4911_CR33","volume-title":"Medicare Benefits Schedule","author":"MBS","year":"2008","unstructured":"MBS: Medicare Benefits Schedule. 2008, Canberra: Department of Health and Ageing, Commonwealth of Australia"},{"key":"4911_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1467-842X.2005.tb00063.x","volume":"29","author":"G Hawthorne","year":"2005","unstructured":"Hawthorne G, Osborne R: Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Publ Health. 2005, 29: 136-142. 10.1111\/j.1467-842X.2005.tb00063.x.","journal-title":"Aust N Z J Publ Health"},{"key":"4911_CR35","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1161\/01.STR.31.9.2087","volume":"31","author":"A Thrift","year":"2000","unstructured":"Thrift A, Dewey H, Macdonell R, McNeil J, Donnan G: Stroke Incidence on the east coast of Australia: The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2000, 31: 2087-2092. 10.1161\/01.STR.31.9.2087.","journal-title":"Stroke"},{"key":"4911_CR36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X06290497","volume":"26","author":"J Hanmer","year":"2006","unstructured":"Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG: Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006, 26: 391-400. 10.1177\/0272989X06290497.","journal-title":"Med Decis Making"},{"key":"4911_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"DG Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R, Klein BEK, Dorn N, Peterson K, Martin PA: The Beaver Dam Health outcomes study: Initial catalog of health state quality factors. Med Decis Making. 1993, 13: 89-102. 10.1177\/0272989X9301300202.","journal-title":"Med Decis Making"},{"key":"4911_CR38","volume-title":"Pharmaceutical Schedule","author":"PHARMAC","year":"2010","unstructured":"PHARMAC: Pharmaceutical Schedule. 2010, New Zealand: Pharmaceutical Management Agency"},{"key":"4911_CR39","volume-title":"Health expenditure Australia","author":"AIHW","year":"2006","unstructured":"AIHW: Health expenditure Australia. 2006, Canberra: Australian Institute of Health and Welfare"},{"key":"4911_CR40","volume-title":"Consumer Price Index, Australia, June quarter","author":"ABS","year":"2006","unstructured":"ABS: Consumer Price Index, Australia, June quarter. 2006, Canberra: Australian Bureau of Statistics"},{"key":"4911_CR41","volume-title":"General Practice in Australia: 2004","author":"Department of Health and Ageing","year":"2005","unstructured":"Department of Health and Ageing: General Practice in Australia: 2004. 2005, Canberra: Commonwealth of Australia"},{"key":"4911_CR42","volume-title":"Cost weight study","author":"KPMG Health Education and Community Services Group","year":"2002","unstructured":"KPMG Health Education and Community Services Group: Cost weight study. 2002, Melbourne, Victoria: Department of Human Services"},{"key":"4911_CR43","volume-title":"Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (NICE clinical guideline 67)","author":"NICE","year":"2008","unstructured":"NICE: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (NICE clinical guideline 67). 2008, UK: National Institute for Health and Clinical Excellence"},{"key":"4911_CR44","volume-title":"Hypertension: clinical management of primary hypertension in adults (NICE clinical guideline 127)","author":"NICE","year":"2011","unstructured":"NICE: Hypertension: clinical management of primary hypertension in adults (NICE clinical guideline 127). 2011, UK: National Institute for Health and Clinical Excellence"},{"key":"4911_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1478-7547-7-10","volume":"7","author":"A Rubinstein","year":"2009","unstructured":"Rubinstein A, Garcia Marti S, Souto A, Ferrante D, Augustovski F: Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc. 2009, 7: 10-10.1186\/1478-7547-7-10.","journal-title":"Cost Eff Resour Alloc"},{"key":"4911_CR46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1520-037X.2007.06423.x","volume":"11","author":"J Newman","year":"2008","unstructured":"Newman J, Grobman WA, Greenland P: Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model. Prev Cardiol. 2008, 11: 36-41. 10.1111\/j.1520-037X.2007.06423.x.","journal-title":"Prev Cardiol"},{"key":"4911_CR47","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"Antithrombotic Trialists Collaboration","year":"2009","unstructured":"Antithrombotic Trialists Collaboration: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009, 373: 1849-1860.","journal-title":"Lancet"},{"key":"4911_CR48","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1467-842X.1998.tb01487.x","volume":"22","author":"MW Knuiman","year":"1998","unstructured":"Knuiman MW, Vu HT, Bartholomew HC: Multivariate risk estimation for coronary heart disease: the Busselton Health Study. Aust N Z J Publ Health. 1998, 22: 747-753. 10.1111\/j.1467-842X.1998.tb01487.x.","journal-title":"Aust N Z J Publ Health"},{"key":"4911_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/174182679600300506","volume":"3","author":"MW Knuiman","year":"1996","unstructured":"Knuiman MW, Vu HTV: Risk factors for stroke mortality in men and women: the Busselton Study. Eur J Cardiovasc Prev Rehabil. 1996, 3: 447-452. 10.1177\/174182679600300506.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"4911_CR50","volume-title":"General Practice in Australia: 2004","author":"Department of Health and Ageing","year":"2005","unstructured":"Department of Health and Ageing: General Practice in Australia: 2004. 2005, Canberra: Commonwealth of Australia"},{"key":"4911_CR51","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/bmj.38849.487546.DE","volume":"332","author":"GM Douglas","year":"2006","unstructured":"Douglas GM, Kelvin K, Peter T, Jenny L, Cameron AM, Geoffrey MA, Sten A, David AA, Andreas L: Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ. 2006, 332: 1419-10.1136\/bmj.38849.487546.DE.","journal-title":"BMJ"},{"key":"4911_CR52","volume-title":"Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (NICE clinical guideline 67)","author":"NICE","year":"2008","unstructured":"NICE: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (NICE clinical guideline 67). 2008, UK: National Institute for Health and Clinical Excellence"},{"key":"4911_CR53","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1161\/hs1001.097222","volume":"32","author":"HM Dewey","year":"2001","unstructured":"Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RAL, McNeil JJ, Donnan GA: Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2001, 32: 2409-2416. 10.1161\/hs1001.097222.","journal-title":"Stroke"},{"key":"4911_CR54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1478-7547-7-10","volume":"7","author":"A Rubinstein","year":"2009","unstructured":"Rubinstein A, Garcia Marti S, Souto A, Ferrante D, Augustovski F: Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc. 2009, 7: 10-10.1186\/1478-7547-7-10.","journal-title":"Cost Eff Resour Alloc"},{"key":"4911_CR55","volume-title":"Economic evaluation in health care: merging theory with practice","author":"A Briggs","year":"2001","unstructured":"Briggs A: Handling uncertainty in economic evaluation and presenting the results. Economic evaluation in health care: merging theory with practice. Edited by: Drummond M, McGuire A. 2001, New York: Oxford University Press"},{"key":"4911_CR56","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2165\/00019053-200119110-00004","volume":"19","author":"B George","year":"2001","unstructured":"George B, Harris A, Mitchell A: Cost-effectiveness analysis and the consistency of decision making: Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). PharmacoEconomics. 2001, 19: 1103-1109. 10.2165\/00019053-200119110-00004.","journal-title":"PharmacoEconomics"},{"key":"4911_CR57","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/S0140-6736(07)61699-7","volume":"370","author":"SS Lim","year":"2007","unstructured":"Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, Rodgers A: Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet. 2007, 370: 2054-2062. 10.1016\/S0140-6736(07)61699-7.","journal-title":"Lancet"},{"key":"4911_CR58","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2471\/BLT.10.082370","volume":"89","author":"R Ndindjock","year":"2011","unstructured":"Ndindjock R, Gedeon J, Mendis S, Paccaud F, Bovet P: Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles. Bull World Health Organ. 2011, 89: 286-295. 10.2471\/BLT.10.082370.","journal-title":"Bull World Health Organ"},{"key":"4911_CR59","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jama.2010.221","volume":"303","author":"FGR Fowkes","year":"2010","unstructured":"Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, Pell ACH, Sandercock PAG, Fox KAA, Lowe GDO, Murray GD: for the Aspirin for Asymptomatic Atherosclerosis T: Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010, 303: 841-848. 10.1001\/jama.2010.221.","journal-title":"JAMA"},{"key":"4911_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW: Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011, 377: 31-41. 10.1016\/S0140-6736(10)62110-1.","journal-title":"Lancet"},{"key":"4911_CR61","volume-title":"Cochrane Database Syst Rev","author":"F Taylor","year":"2011","unstructured":"Taylor F, Ward K, Moore T, Burke M, Davey Smith G, Casas J, Ebrahim S: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011"},{"key":"4911_CR62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5694\/j.1326-5377.2011.tb04157.x","volume":"194","author":"PM Clarke","year":"2011","unstructured":"Clarke PM, Fitzgerald EM: Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia [Letter]. Med J Aust. 2011, 194: 53-54.","journal-title":"Med J Aust"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2458-12-398\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-12-398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-12-398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-12-398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T10:59:54Z","timestamp":1594205994000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-12-398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["4911"],"URL":"https:\/\/doi.org\/10.1186\/1471-2458-12-398","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,1]]},"article-number":"398"}}